Last month (May 2016), we released chemPK™ v.2 for predicting human pharmacokinetics directly from chemical structure. The new version has enhanced functionality and enables both IV and oral administration to be simulated as well as repeat dose regimens. In June, we've built further on that service with chemTarget – a virtual screening tool for predicting biological target interaction from chemical structure. By integrating chemTarget with chemPK™, an extremely powerful system has been developed which can provide in-depth biological target engagement parameters.
Endocrine disruption is a hot topic, with several regulatory authorities planning reform in terms of the testing requirements. In June, we launched our Androgen Receptor modulation assay. This assay uses high content imaging which enables androgen receptor translocation from the cytoplasm to the nucleus to be visualised and measured using fluorescently tagged proteins. As well as androgen receptor activation, the assay can also detect androgen receptor antagonists which has application in drug discovery screening for prostate cancer therapies. The new assay complements our existing screening and regulatory endocrine disruption services.
Amidst these launches, research has not slowed down. We have presented our research at the Clinically Relevant Drug Transporters meeting in Berlin and ISSX in South Korea.